SG Americas Securities
BBC icon

SG Americas Securities’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

SG Americas Securities’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-34,009
Closed -$818K – 3479
2017
Q2 		$818K Buy
34,009
+4,205
+14% +$94.2K 0.01% 1546
2017
Q1 		$691K Sell
29,804
-4,179
-12% -$88.8K 0.01% 1630
2016
Q4 		$625K Buy
33,983
+3,613
+12% +$72.1K 0.01% 1568
2016
Q3 		$688K Buy
30,370
+21,970
+262% +$450K 0.01% 1443
2016
Q2 		$151K Buy
+8,400
New +$165K ﹤0.01% 2226

Other funds holding BBC

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
CCP
Cardan Capital Partners Denver, Colorado $893M AUM 22.82% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AWM
Avior Wealth Management Omaha, Nebraska $3.8B AUM 23.28% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

SG Americas Securities's BBC Position: Q3 2017 in Review

SG Americas Securities sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q3 2017, closing a stake of 34,009 shares — an estimated $818K sold.

SG Americas Securities first reported a position in BBC in Q2 2016 and held it in 5 quarters. The position peaked at $818K in Q2 2017. 10 funds tracked by Wall St. Rank hold BBC as of Q3 2017.

  • SG Americas Securities reported no remaining Virtus Biotech Clinical Trials ETF position as of Q3 2017 after selling out during the quarter.
  • SG Americas Securities sold 34,009 Virtus Biotech Clinical Trials ETF shares in Q3 2017, an estimated $818K.
  • SG Americas Securities first reported a position in Virtus Biotech Clinical Trials ETF in Q2 2016 and held it in 5 quarters.
  • SG Americas Securities's Virtus Biotech Clinical Trials ETF position peaked at $818K in Q2 2017.
  • 10 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q3 2017.

Based on SG Americas Securities's 13F filing for Q3 2017, filed 7 Nov 2017.